




Searching News Database: Bioral
HSMN NewsFeed - 10 Jan 2008
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
FDA Accepts for Filing the BEMA(TM) Fentanyl NDA from BioDelivery Sciences
HSMN NewsFeed - 14 Aug 2007
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
BDSI Names David Blum, M.D. Vice President of Medical Affairs and Clinical Research
HSMN NewsFeed - 14 May 2007
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
BDSI Announces Positive Key Secondary Efficacy Endpoint Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 25 Apr 2007
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
BDSI Announces Positive Phase III Clinical Trial Results for BEMA(TM) Fentanyl
HSMN NewsFeed - 3 Aug 2006
BDSI Announces Purchase of Non-U.S. BEMA(TM) Technology from QLT USA, Inc.
BDSI Announces Purchase of Non-U.S. BEMA(TM) Technology from QLT USA, Inc.
HSMN NewsFeed - 9 Jan 2006
BioDelivery Sciences Hires Proven Pharmaceutical Executive To Head Sales and Marketing Effort
BioDelivery Sciences Hires Proven Pharmaceutical Executive To Head Sales and Marketing Effort
HSMN NewsFeed - 6 Jan 2006
BioDelivery Sciences Files IND for BEMA(TM) LA, a Treatment for Moderate to Severe Pain
BioDelivery Sciences Files IND for BEMA(TM) LA, a Treatment for Moderate to Severe Pain
Additional items found! 12

Members Archive contains
12 additional stories matching:
Bioral
(Password required)
Bioral
(Password required)